Home » Topics » Ocular, BioWorld Science

Ocular, BioWorld Science
RSS

InSite Vision and Ciba Vision marketing agreement for sustained-release eyedrop formulation

June 7, 1996

Ofloxacin ophthalmic solution receives FDA approval

May 31, 1996

Carbonic anhydrase inhibitors from Alcon

May 31, 1996

Anti-VEGF oligonucleotides inhibit retinal neovascularization in preclinical model

May 17, 1996

SnET2 enters phase I/II for AMD indication

May 17, 1996

Pharmos, Bausch & Lomb expand Lotemax agreement

May 17, 1996

Dorzolamide approved for marketing in Canada

May 17, 1996

AI-300 effective in preliminary clinical study

May 10, 1996

Verteporfin effective in treating severe age-related macular degeneration in early trials

May 3, 1996

Toray's MIP for treatment of ophthalmological disorders

May 3, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 27, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 27, 2025
New drugs with the same old resistance tricks?
BioWorld
According to the World Health Organization (WHO), multidrug-resistant pathogens caused over 1.27 million deaths worldwide in 2020. And figures are rising, with...
OS Therapies heading to FDA with positive osteosarcoma data
BioWorld
With positive data in hand from its phase IIb trial testing immunotherapy candidate OST-HER2 in osteosarcoma, OS Therapies Inc. anticipates a regulatory filing...
Vilastobart set apart? Xilio phase II combo performs in CRC
BioWorld
“The [colorectal cancer field is moving, and thankfully it’s moving quickly,” said Marwan Fakih, gastrointestinal specialist at City of Hope, speaking about...